Erasca, Inc.
16.82USD
+1.1200 (+7.13%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-0.13▼ | $-0.12 | 2 | 5 |
| Next quarter | $-0.13▲ | $-0.14 | 4 | 4 |
| Current year | $-0.98▼ | $-0.97 | 3 | 6 |
| Next year | $-0.62▼ | $-0.57 | 2 | 7 |
Beat in 1 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-0.11 | $-0.14 | -0.03 (-25.3%) |
| 2026-03-31 | $-0.23 | $-0.6 | -0.37 (-166.0%) |
| 2025-12-31 | $-0.11 | $-0.1 | +0.01 (+6.0%) |
| 2025-09-30 | $-0.11 | $-0.11 | -0.00 (-4.5%) |
55 ratings from 14 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| B of A Securities | Maintained | Neutral | $18 $20 | Aug 14, 2026 |
| Guggenheim | Maintained | Buy | $20 $21 | Aug 13, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $18 $22 | Aug 12, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $12 $21 | Jul 20, 2026 |
| B of A Securities | Maintained | Neutral | $16 $18 | Jul 14, 2026 |
| B of A Securities | Upgraded from Underperform | Neutral | $9 $16 | Jun 4, 2026 |
| Mizuho | Maintained | Outperform | $28 $26 | May 12, 2026 |
| Stifel | Maintained | Buy | $20 $30 | Apr 27, 2026 |
| JP Morgan | Maintained | Overweight | $24 $25 | Mar 18, 2026 |
| Guggenheim | Maintained | Buy | $12 $20 | Mar 16, 2026 |
| Piper Sandler | Maintained | Overweight | $11 $18 | Mar 13, 2026 |
| Mizuho | Maintained | Outperform | $16 $19 | Mar 13, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $15 $20 | Mar 13, 2026 |
| Clear Street | Maintained | Buy | $11 $20 | Mar 6, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $11 $15 | Jan 26, 2026 |
| Piper Sandler | Maintained | Overweight | $5 $11 | Jan 16, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $6 $11 | Jan 13, 2026 |
| Piper Sandler | Initiated | Overweight | $5 | Jan 7, 2026 |
| Mizuho | Maintained | Outperform | $4 $5 | Dec 9, 2025 |
| Guggenheim | Maintained | Buy | $3 $5 | Nov 14, 2025 |
| Stifel | Initiated | Buy | $4 | Oct 16, 2025 |
| B of A Securities | Downgraded from Buy | Underperform | $4 $1 | Sep 3, 2025 |
| Morgan Stanley | Downgraded from Overweight | Equal-Weight | $4 $2 | Aug 18, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $6 | Apr 30, 2025 |
| Raymond James | Initiated | Outperform | $5 | Mar 26, 2025 |
8 filings from 3 insiders · 1 buy / 1 sell over 6m
Officers and directors of ERAS, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| GARNER EBUN SOfficer | Sell | 80.0k | $16.40 | $1.31M | Apr 1, 2026 |
| GARNER EBUN SOfficer | Exercise | 80.0k | $1.70 | $136k | Apr 1, 2026 |
| MORRIS SHANNON R. M.D., PH.D.Officer | Sell | 20.0k | $15.04 | $301k | Mar 4, 2026 |
| MORRIS SHANNON R. M.D., PH.D.Officer | Exercise | 20.0k | $1.70 | $34k | Mar 4, 2026 |
| GARNER EBUN SGeneral Counsel | Sell | 120.0k | $5.59 | $671k | Jan 7, 2026 |
| GARNER EBUN SGeneral Counsel | Exercise | 120.0k | $1.70 | $204k | Jan 7, 2026 |
| GARNER EBUN SGeneral Counsel | Grant | 3.9k | $3.43 | $13k | Dec 15, 2025 |
| MULTANI PRATIK SDirector | Gift | 6.2k | — | — | May 23, 2025 |
No analyst notes on ERAS yet.
Analyst Ratings
9 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 5 | 2 | 0 | 0 | Buy2.00 |
| 1 mo ago | 2 | 6 | 2 | 0 | 0 | Buy2.00 |
| 2 mo ago | 2 | 6 | 2 | 0 | 0 | Buy2.00 |
| 3 mo ago | 2 | 6 | 2 | 0 | 0 | Buy2.00 |